Biogen, Eisai Get FDA Nod for Leqembi IV Maintenance Dosing
Biogen and Eisai have won Food and Drug Administration approval of an intravenous maintenance dosing of their Leqembi drug for early Alzheimer's disease. The companies late Sunday said the FDA approved the maintenance dosing of once every four weeks after 18 months of the initiation phase of once every two weeks.
The post 3 Furnace Maintenance Tips Recommended by HVAC Experts To Save You Money appeared first on Real Estate News & ...
Maintenance costs are a significant factor for many buyers when selecting an SUV. While SUVs offer numerous advantages, such ...
For organizations considering the adoption of scalable AI for demand forecasting, it’s essential to approach implementation ...
Convenience has become a priority for consumers. From streaming services to meal kits, subscription models have ...
The National Audit Office Ministers has also warned ministers that allowing the waiting list of repairs to linger is a ‘false ...
When it comes to safeguarding the community from the destructive power of heavy rains and flooding, Woodlands Water is taking ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback